Boston Scientific Corporation
Boston Scientific shares weakened after quarterly results and CHAMPION-AF data failed to provide the positive catalyst investors had hoped for. U.S. Electrophysiology and…
BSX
2 published ideas on Boston Scientific Corporation across 2 funds — 2 long and 0 short.
Each stock pitch below comes from a fund manager's own investor letter, not a 13F filing, so it carries the reasoning behind the portfolio position on Boston Scientific: the full investment thesis, the risks the manager flagged, the conviction level and the time horizon. Positions may have changed since the letter was written.
Boston Scientific shares weakened after quarterly results and CHAMPION-AF data failed to provide the positive catalyst investors had hoped for. U.S. Electrophysiology and…
The Insiders Fund sees Boston Scientific as a potential longer-term beneficiary of aging populations and sustained demand for medical technologies. Its cardiology…